dc.contributor.author |
Thabrew, M.I. |
en_US |
dc.contributor.author |
Hughes, R.D. |
en_US |
dc.contributor.author |
Mcfarlane, I.G. |
en_US |
dc.date.accessioned |
2014-10-29T09:15:08Z |
|
dc.date.available |
2014-10-29T09:15:08Z |
|
dc.date.issued |
1997 |
en_US |
dc.identifier.citation |
Journal of Pharmacy and Pharmacology. 1997; 49(11): 1132-1135 |
en_US |
dc.identifier.issn |
0022-3573 (Print) |
en_US |
dc.identifier.issn |
2042-7158 (Electronic) |
en_US |
dc.identifier.uri |
http://repository.kln.ac.lk/handle/123456789/1318 |
|
dc.description |
Indexed in MEDLINE |
|
dc.description.abstract |
Identification of the active components of plants with hepatoprotective properties requires screening of large numbers of samples during fractionation and purification. A screening assay has been developed based on protection of human liver-derived HepG2 cells against toxic damage. Various hepatotoxins were incubated with HepG2 cells in 96-well microtitre plates (30,000 cells well-1) for 1 h and viability was determined by metabolism of the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS). Bromobenzene (10 mM) and 2,6-dimethyl-N-acetyl-p-quinoneimine (2,6-diMeNAPQI, 200 mM) had greater toxic effects than tert-butyl hydroperoxide (1.8 mM) or galactosamine (10 mM), reducing mean viability to 44.6 +/- 1.2% (s.e.m.) and 56.1 +/- 2.1% of control, respectively. Protection against toxic damage by these agents was tested using a crude extract of a known hepatoprotective Sri Lankan plant, Osbeckia aspera, and two pure established hepatoprotective plant compounds, (+)-catechin and silymarin (1 mg mL-1). Viability was significantly improved by Osbeckia (by 37.7 +/- 2.4%, P < 0.05, and 36.5 +/- 2.1%, P < 0.05, for bromobenzene and 2,6-diMeNAPQI toxicity, respectively). Comparable values for (+)-catechin were 68.6 +/- 2.9% and 63.5 +/- 1.1%, and for silymarin 24.9 +/- 1.4% and 25.0 +/- 1.6%. This rapid and reproducible assay should prove useful for the isolation and identification of active hepatoprotective compounds in crude plant extracts. |
|
dc.publisher |
Wiley |
en_US |
dc.subject |
Plant Extracts |
|
dc.subject |
Plant Extracts-therapeutic use |
|
dc.subject |
Liver-drug effects |
|
dc.subject |
Cell Survival-drug effects |
|
dc.subject |
Drug Evaluation, Preclinical-methods |
|
dc.subject |
Bromobenzenes-toxicity |
|
dc.subject |
Catechin-therapeutic use |
|
dc.subject |
Silymarin-therapeutic use |
|
dc.title |
Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay |
en_US |
dc.type |
Article |
en_US |
dc.identifier.department |
Biochemistry |
en_US |
dc.creator.corporateauthor |
Pharmaceutical Society of Great Britain |
en_US |
dc.creator.corporateauthor |
Royal Pharmaceutical Society of Great Britain |
en_US |
dc.creator.corporateauthor |
British Pharmaceutical Conference |
en_US |